Direskeneli Haner
Division of Rheumatology, Department of Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey.
Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):189-193. Epub 2017 Mar 27.
Takayasu's arteritis (TAK) is a rare, chronic, large-vessel vasculitis (LVV) that predominantly affects aorta, its major branches and the pulmonary arteries. Recent controversial issues in the diagnosis, disease assessment and prognosis in TAK are discussed in this review. In recent years, conventional angiography, the standard method for the initial diagnosis, seems to have been replaced by the new imaging modalities, such as MRI and 18F-FDG-PET. Less invasive techniques (CT/MRI) are now suggested first, compared to conventional angiography, and MRI is preferable to CT with less contrast load/radiation. Ultrasound is useful for carotid assessment, but being a user-dependent technique, imaging of deeper vessels (subclavian and aorta) are not reliable. 18F-FDG-PET is useful especially in patients with no vascular symptoms/signs, fever of unknown origin or unexplained acute-phase response. MRI and 18F-FDG-PET are also promising for the assessment of disease activity. New tools for disease assessment such as Indian Takayasu Arteritis Score (ITAS2010) aim to better characterise and quantify disease activity. Prognosis is recently possibly getting better with lower mortality, but a substantial damage is present even in early cases. There is a clear need to develop a validated set of outcome measures to be used in clinical trials of TAK. The OMERACT Vasculitis Working Group has taken on this task, finished a Delphi exercise with experts and aims to develop a core set of outcomes for LVV.
高安动脉炎(TAK)是一种罕见的慢性大血管血管炎(LVV),主要累及主动脉、其主要分支和肺动脉。本综述讨论了TAK在诊断、疾病评估和预后方面最近存在争议的问题。近年来,作为初始诊断的标准方法,传统血管造影似乎已被MRI和18F-FDG-PET等新的成像方式所取代。与传统血管造影相比,现在首先建议采用侵入性较小的技术(CT/MRI),并且MRI优于CT,其造影剂负荷/辐射较小。超声对颈动脉评估有用,但作为一种依赖操作者的技术,对更深层血管(锁骨下动脉和主动脉)的成像并不可靠。18F-FDG-PET尤其适用于无血管症状/体征、不明原因发热或不明原因急性期反应的患者。MRI和18F-FDG-PET在评估疾病活动度方面也很有前景。诸如印度高安动脉炎评分(ITAS2010)等疾病评估新工具旨在更好地描述和量化疾病活动度。最近预后可能有所改善,死亡率降低,但即使在早期病例中也存在严重损害。显然需要开发一套经过验证的结局指标,用于TAK的临床试验。OMERACT血管炎工作组已承担此项任务,与专家完成了德尔菲法,并旨在为LVV制定一套核心结局指标。